The Belmont Report: 3 essential principles behind every clinical trial
Before a single participant can be enrolled in a clinical trial, before a consent form is signed, before a protocol is approved by an ethics committee, three ethical principles must be satisfied. These principles, respect for persons, beneficence, and justice, are the foundation of every standard that governs clinical research today. They originate from a single document: the Belmont Report.
Published in 1979 by the United States National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, the Belmont Report is one of the most consequential documents in the history of medicine. It did not emerge from academic philosophy. It emerged from crisis, from the revelation that research conducted under the authority of the medical profession had caused systematic, deliberate harm to vulnerable human beings. Understanding the Belmont Report means understanding why the ethical standards we take for granted in clinical research today were not always present, and why they must never be taken for granted again.
This guide covers everything: what the Belmont Report is, what its three principles mean in practice, why it was written, and how it formed the direct ethical lineage that runs through the Declaration of Helsinki and into the ICH GCP guidelines that govern clinical research worldwide today.
The Belmont Report is the 1979 document that established the three fundamental ethical principles governing all research involving human participants: respect for persons, beneficence, and justice. Its principles underpin every requirement in today’s ICH GCP good clinical practice guidance, from informed consent through to independent ethics committee review.
What is the Belmont Report?
The Belmont Report definition
The Belmont Report is a landmark document in the history of research ethics, published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research in the United States. It establishes three fundamental ethical principles that must govern all research involving human participants: respect for persons, beneficence, and justice. It also describes how these principles translate into specific research requirements: informed consent, assessment of risks and benefits, and the fair selection of research participants.
The report takes its name from the Belmont Conference Center at the Smithsonian Institution in Elkridge, Maryland, where the National Commission convened the meetings that produced its foundational statements. It was formally published in the Federal Register on 18 April 1979 and has since become the cornerstone reference for research ethics in the United States and, through its influence on subsequent international frameworks, across the global clinical research community.
The Belmont Report is not a regulatory instrument; it does not itself carry the force of law. Its authority derives from its clarity, its moral force, and its adoption as the foundational framework by regulatory bodies, ethics committees, and international standard-setting organisations around the world. The ICH GCP good clinical practice guidance for conducting clinical trials traces every requirement, directly or indirectly, to the ethical principles articulated in the Belmont Report.
The Belmont Report distinction: where does clinical practice end and research begin?
Many clinical researchers, especially investigators new to GCP, genuinely struggle to understand when their clinical activity crosses the line from standard medical practice into research requiring ethics oversight and GCP compliance. The Belmont Report’s answer is precise: practice is designed solely to enhance the well-being of an individual patient. Research is designed to test a hypothesis and produce generalizable knowledge. When a clinician departs significantly from standard practice, the innovation is not automatically researched, but it should be made the subject of formal research at an early stage to establish whether it is safe and effective.
Why was the Belmont Report written?
The Belmont Report was written in direct response to the Tuskegee Syphilis Study, one of the most egregious ethical violations in the history of medical research. From 1932 to 1972, the United States Public Health Service conducted a study on 399 Black men in Alabama who had syphilis, telling participants they were being treated for “bad blood” (“bad blood” was a local colloquial term covering a range of ailments, and many participants did not know they had syphilis specifically) while deliberately withholding effective antibiotic treatment that became available in the 1940s. The men were observed as the disease progressed, without their knowledge or consent, for four decades. The study only ended after a whistleblower’s disclosure led to public outrage and congressional investigation.
The revelation of the Tuskegee study in 1972 prompted the United States Congress to pass the National Research Act of 1974, which created the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Commission’s mandate was to identify the basic ethical principles that should govern all biomedical and behavioral research involving human subjects, and to develop guidelines to ensure that research was conducted in accordance with those principles. The Belmont Report was the Commission’s primary output, the document that fulfilled that mandate.
Tuskegee was the most publicly visible catalyst, but the National Commission’s mandate was also shaped by other documented abuses. The Willowbrook hepatitis studies, in which children with intellectual disabilities at a New York institution were deliberately infected with hepatitis B between 1956 and 1970, and the Jewish Chronic Disease Hospital case of 1963, in which cancer cells were injected into elderly patients without their knowledge, had each exposed the absence of adequate ethical oversight in American research. The Belmont Report addressed all of these failures collectively.
The purpose of the 1979 Belmont Report was therefore both retrospective and prospective: to explain why what had happened in Tuskegee was wrong, to identify the principles whose violation had made it wrong, and to ensure that those principles were embedded into every future research endeavor involving human participants. This is why the Belmont Report carries a moral authority that goes beyond its formal regulatory status; it was written not in the abstract but in direct response to documented human suffering caused by the absence of ethical oversight.
The Belmont Report and its historical predecessors
The Belmont Report did not emerge in isolation. It was the culmination of a succession of ethical responses to abuses of research participants that had accumulated over the preceding decades.
The Nuremberg Code, published in 1947 following the Doctors’ Trials after World War II, was the first international articulation of the principle that voluntary, informed consent is an absolute requirement for participation in human research. It was written in direct response to the systematic medical experimentation conducted on concentration camp prisoners by Nazi physicians, experiments conducted without consent, often with lethal results. The Nuremberg Code established ten principles for ethical human experimentation, with voluntary consent as the most fundamental. However, the Nuremberg Code was not widely adopted in practice, and its principles were not systematically applied to the research programmes of democratic governments and established medical institutions.
The Declaration of Helsinki, first adopted by the World Medical Association in 1964, built on the Nuremberg Code to create a more comprehensive ethical framework specifically for medical research. It distinguished between therapeutic and non-therapeutic research, emphasised the physician-researcher’s responsibility to the participant as a patient, and introduced the concept of independent ethics committee review. The Declaration of Helsinki has been revised multiple times since 1964, most recently in 2024, and remains one of the primary international reference documents for research ethics. However, the medical profession primarily addresses it but lacks regulatory authority over the broader research ecosystem.
The Belmont Report completed this lineage by providing a philosophical and practical framework that could be operationalised across all types of research involving human participants, not only medical research conducted by physicians but also behavioural and social science research, government-sponsored research, and the full range of clinical investigation that constitutes modern clinical research.
The most direct regulatory legacy of the Belmont Report in the United States is 45 CFR 46, known as the Common Rule, the federal regulation that governs research involving human participants at all institutions receiving federal funding, incorporating the Belmont Report’s principles into binding legal requirements.
What are the 3 principles of the Belmont Report?
The three principles of the Belmont Report are the ethical pillars on which all ethical clinical research is built. Understanding them is not merely of academic interest; they are the reasoning behind every requirement in ICH GCP good clinical practice training and every document a clinical research professional handles.
Principle 1: Respect for persons
The first of the three Belmont Report principles is respect for persons. This principle has two components: the recognition that individuals are autonomous agents capable of making their own decisions, and the requirement that individuals with diminished autonomy, including children, people with cognitive impairments, and prisoners, are entitled to additional protections.
Respect for persons generates the requirement for informed consent in clinical research. If a person is an autonomous agent capable of making their own decisions, then a researcher has no right to involve that person in a study without first ensuring that the person understands what the research involves and has freely chosen to participate. Consent must be informed, the participant must receive sufficient information to make a meaningful decision, and it must be voluntary, free from coercion, undue influence, or deception.
In the context of modern ICH GCP good clinical practice guidance, the principle of respect for persons is operationalised through the entire informed consent framework: the requirement that consent be obtained before any study procedure begins, that the consent form be written in language the participant can understand, that participants be given adequate time to consider, that they be informed of their right to withdraw at any time, and that re-consent be obtained when new information emerges that might affect their decision to continue.
The principle of respect for persons also underpins the additional protections required for vulnerable populations in clinical research, the heightened ethics committee scrutiny applied to studies involving children, pregnant women, prisoners, and cognitively impaired adults. These groups are not excluded from clinical research. Still, they are recognised as populations whose capacity for autonomous decision-making may be diminished or whose circumstances may compromise the voluntariness of consent, requiring additional safeguards.
For a detailed breakdown of how the informed consent process works in clinical trials and what ICH GCP requires, see our complete guide to informed consent in clinical trials.
Principle 2: Beneficence
The second Belmont Report principle is beneficence. This principle goes beyond the Hippocratic obligation to avoid harm, it requires researchers to actively maximise potential benefits and minimise potential harms. The Belmont Report formulates this as two complementary rules: do not harm, and maximise possible benefits while minimising possible harms. Beneficence, as articulated in the Belmont Report, applies at two levels: the level of the individual participant and the level of society. At the individual level, researchers must design studies that expose participants to the minimum risk necessary to achieve the scientific objectives. At the societal level, the Belmont Report acknowledges that clinical research necessarily involves some degree of risk to current participants in order to generate knowledge that will benefit future patients, and requires that this tension be managed through rigorous risk-benefit assessment.
In ICH GCP good clinical practice training, the principle of beneficence is operationalised primarily through the requirements for independent ethics committee review, risk-benefit assessment, and safety monitoring throughout the trial. An independent ethics committee, known as an Institutional Review Board (IRB) in the United States, reviews every study before it begins specifically to assess whether the anticipated benefits to knowledge and to future patients justify the risks to current participants. Continuous safety monitoring during the trial, including the requirement to report and assess adverse events and serious adverse events, reflects the ongoing obligation of beneficence throughout the participant’s involvement.
The principle of beneficence also underpins the requirement in the ICH GCP guidance that a trial be discontinued when the emerging data indicate that the risks to participants outweigh the benefits, or when a new treatment has been demonstrated to be so superior to the comparator that continuing to deny it to control group participants would be unethical.
Principle 3: Justice
The third of the three Belmont Report principles is justice, the fair distribution of both the benefits and the burdens of research. This principle addresses a specific and important concern: that throughout history, the burdens of research have disproportionately fallen on vulnerable, disadvantaged, or powerless populations, while the benefits of the resulting treatments have been enjoyed primarily by more privileged groups.
The Tuskegee study was itself a profound example of injustice in clinical research: Black, impoverished men in rural Alabama bore the burden of the study’s risks and harms, while gaining no benefit, so that knowledge could be acquired that would primarily benefit the broader population. The Belmont Report’s principle of justice requires that participant selection be fair, that groups are not selected for research participation because they are convenient to recruit or easy to exploit, and that groups who will benefit from the eventual results of research share equitably in the risks of the research process.
In contemporary clinical research, the principle of justice has generated increasingly specific requirements in both regulatory guidance and ethics committee practice. It underpins the requirement that clinical trials enroll diverse participant populations representative of the patients who will ultimately use the treatment. The current emphasis in ICH GCP E6 R3 and in FDA and EMA guidance on diversity and inclusion in clinical trials reflects the enduring force of the justice principle. It also underpins the obligation to conduct research in resource-limited countries only when the knowledge generated will apply and accessible to the populations in those countries who participated.
Justice as a Belmont Report principle also requires equitable sharing of the benefits of research. Where a clinical trial is conducted in a developing country, the principle of justice demands that any effective treatment demonstrated by the trial be made accessible to participants and their communities, not withdrawn at the trial’s conclusion to be exploited exclusively in more commercially lucrative markets.
How the Belmont Report translates its 3 principles into 3 practical requirements
Belmont Report principle | Practical application |
Respect for persons | Informed consent |
Beneficence | Assessment of risks and benefits |
Justice | Selection of subjects |
The Belmont Report to ICH GCP: the ethical lineage
From the Belmont Report to the Declaration of Helsinki
The Belmont Report and the Declaration of Helsinki are parallel rather than sequential documents; the Declaration predates the Belmont Report by fifteen years. However, the two frameworks reinforce each other and, taken together, constitute the ethical foundation on which the ICH GCP guidance was built.
Where the Belmont Report provides a philosophical framework, three principles from which all specific research ethics requirements can be derived, the Declaration of Helsinki provides a more detailed set of practical standards addressed specifically to physicians conducting medical research. The Declaration introduced concepts including the obligation to register clinical trials on publicly accessible databases, the requirement for independent ethics committee review, the distinction between the therapeutic interests of the individual patient and the scientific interests of the research, and the obligation to share research results publicly regardless of whether they are positive or negative.
The 2024 revision of the Declaration of Helsinki continued this evolution, strengthening requirements around diversity, post-trial access to proven treatments, and the ethical oversight of research involving artificial intelligence and digital health technologies. For professionals seeking ICH GCP certification, understanding the Declaration of Helsinki is as important as understanding the Belmont Report, both documents provide the ethical reasoning that the technical requirements of good clinical practice translate into practical compliance obligations.
For a detailed guide to the Declaration of Helsinki and its most recent revision, see our guide to the new Declaration of Helsinki 2024.
From the Declaration of Helsinki to ICH GCP
The ICH GCP E6 guidance, the international standard for good clinical practice in clinical trials, was developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and first adopted in 1996. It was created to harmonise the often differing GCP requirements of the United States, Europe, and Japan into a single global standard that could support multinational drug development and regulatory submission.
ICH GCP E6 draws directly and explicitly on the ethical principles of the Belmont Report and the Declaration of Helsinki. The first principle of ICH GCP E6 R3, the current version of the guideline, states: “Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with GCP and applicable regulatory requirements.” Every subsequent principle and requirement in the guideline is, at its root, a practical expression of one or more of the three Belmont Report principles.
The principle of respect for persons becomes the ICH GCP requirements for informed consent, participant confidentiality, and the additional protections for vulnerable populations. The principle of beneficence becomes the requirements for independent ethics committee review, risk-benefit assessment, adverse event monitoring, and safety reporting. The principle of justice becomes the requirements for equitable participant selection, diversity in trial populations, and the prohibition on exploiting vulnerable groups for the convenience of researchers or sponsors.
When clinical research professionals complete ICH GCP good clinical practice training or pursue ICH GCP good clinical practice certification, they are not simply learning a set of procedural rules. They are engaging with an ethical framework whose roots go back to the Belmont Report’s response to documented human suffering. Understanding this lineage transforms the experience of GCP training from compliance learning to genuine ethical engagement.
For a complete guide to the ICH GCP principles and how they apply in practice, see our guide to the principles of ICH GCP.
How the Belmont Report shaped today's ICH GCP requirements
Informed consent: the Belmont Report's most visible legacy
Of all the requirements in ICH GCP good clinical practice guidance, the informed consent framework is the most directly traceable to the Belmont Report. The document’s treatment of respect for persons generated specific requirements that appear, sometimes almost word-for-word, in the ICH GCP guidance.
The requirement that consent be voluntary: directly from the Belmont Report’s insistence that respect for persons prohibits coercion and undue influence. The requirement that information be understandable: from the Belmont Report’s recognition that information must be presented in a form that is comprehensible to the participant, not simply provided in a legal or technical format. The requirement for ongoing consent throughout the trial: from the Belmont Report’s treatment of autonomy as continuous rather than exercised only at the point of enrolment. The requirement for additional protections for vulnerable populations, from the Belmont Report’s recognition that diminished autonomy requires compensating safeguards.
ICH GCP E6 R3, the current standard for good clinical practice training and certification, has extended the Belmont Report’s informed consent requirements into the digital era through its explicit endorsement of eConsent and multimedia tools, while maintaining the principle that the goal of consent is genuine participant understanding, not formal documentation.
Ethics committee review: institutionalising beneficence and justice
The requirement for an independent ethics committee to review all clinical research is one of the most operationally significant aspects of ICH GCP good clinical practice and reflects both the beneficence and justice principles of the Belmont Report.
Beneficence is served by the ethics committee’s role in assessing whether the risks of a proposed study are justified by the anticipated benefits, an independent assessment that prevents the interests of the sponsor or the scientific enthusiasm of the investigator from distorting the risk-benefit calculation. Justice is served by the ethics committee’s role in reviewing participant selection, ensuring that vulnerable populations are not disproportionately burdened with research risk, and that the populations most likely to benefit from the eventual treatment are equitably represented among those asked to bear the risks of the research process.
For principal investigators and site staff who have completed ICH GCP good clinical practice training, understanding why ethics committee review exists, and what the committee is actually assessing, transforms the experience of preparing ethics submissions from a bureaucratic exercise into a genuine ethical responsibility. See our guide to principal investigator responsibilities under ICH GCP for a detailed breakdown of the investigator’s obligations in this process.
Risk-benefit assessment: the operational expression of beneficence
The requirement in ICH GCP that every clinical trial be assessed for the balance of risks and benefits, before initiation, throughout conduct, and at the point of any decision to continue or stop, is the direct operational expression of the Belmont Report’s beneficence principle.
The Belmont Report introduced the concept of systematic, prospective risk-benefit assessment as a requirement for ethical research. Before the Belmont Report, research often proceeded on the basis that the knowledge to be gained justified the risks participants might bear, a calculation made by investigators without independent oversight or structured methodology. The Belmont Report made risk-benefit assessment a formal, documented, multi-stakeholder process, a process now embedded in ICH GCP good clinical practice guidance as a requirement for ethics committee review, protocol design, and safety monitoring.
ICH E6 R3’s emphasis on quality by design and proportionate risk management, one of the most significant innovations of the current good clinical practice guidance, is also traceable to the beneficence principle. The requirement that trial processes be proportionate to the risks to participants and the importance of the data being collected is, at its root, an expression of the Belmont Report’s insistence that research risk be systematically minimized rather than accepted as an unavoidable feature of the scientific enterprise.
Diversity and justice: the Belmont Report's evolving legacy
The justice principle of the Belmont Report has found its most contemporary expression in the growing regulatory emphasis on diversity, equity, and inclusion in clinical trials. For decades after the Belmont Report was published, clinical research continued to systematically under-represent women, elderly patients, and non-white populations in clinical trials, creating an evidence base that was generated primarily in one population but applied globally to all populations.
Regulatory authorities including the FDA and EMA have increasingly translated the Belmont Report’s justice principle into specific guidance on the inclusion of diverse populations in clinical trials. ICH E6 R3’s strengthened language on participant diversity and the explicit requirement that trial populations be representative of the patients who will ultimately receive the treatment reflect the continued evolution of the Belmont Report’s foundational principle into contemporary practice.
For clinical research professionals working toward ICH GCP good clinical practice certification, understanding this justice principle is not merely of historical interest. It shapes the way protocols are designed, the way recruitment strategies are developed, and the way ethics committees evaluate the fairness of research proposals.
The Belmont Report in clinical research today
Why the Belmont Report still matters in 2026
The Belmont Report was published in 1979, more than forty-five years ago. Yet its principles have not been superseded by subsequent frameworks; they have been built upon, extended, and operationalized into increasingly detailed regulatory requirements. This is because the Belmont Report identified genuinely foundational principles: they are not specific to any particular technology, therapeutic area, or research design, and they do not become obsolete as medical science and clinical practice evolve.
The emergence of artificial intelligence in clinical research, the growing use of real-world data and decentralized trial models, and the increasing complexity of genomic and personalized medicine research all raise new ethical questions, but they are questions that can be analyzed and resolved using the three Belmont Report principles. Does this technology respect the autonomy of research participants? Does this study design minimize harm and maximize benefit? Does this approach to participant recruitment distribute the burdens and benefits of research fairly? If these three questions can be answered affirmatively, a research programme is on firm ethical ground. If they cannot, the Belmont Report tells us why and what must change.
For clinical research professionals completing ICH GCP good clinical practice training or ICH GCP good clinical practice certification in 2026, the Belmont Report provides something that technical compliance training rarely does: the moral reasoning that explains why each requirement exists. This understanding is what transforms a competent GCP practitioner into an ethical one.
The Belmont Report and the ICH GCP E6 R3 update
The current version of the good clinical practice guidance, ICH GCP E6 R3, which was adopted in January 2025, strengthens the principles of the Belmont Report in a number of important ways. The new emphasis on quality by design, identifying the elements of a trial that are most important to participant safety and data integrity before a single participant is enrolled, is an expression of beneficence: building protection into the system rather than relying on error correction after harm has occurred.
The stronger language on proportionality in R3, which says that research processes must be proportionate to the risks they manage, is based on the Belmont Report’s risk-benefit framework. The explicit acknowledgement of diversity and inclusion in R3 extends the Belmont Report’s justice principle into specific operational guidance for the first time in the ICH GCP framework.
Understanding the Belmont Report’s principles provides a stable ethical anchor for professionals who have completed good clinical practice training under R2 and are now pursuing updated ICH GCP good clinical practice certification under R3, helping them navigate the technical changes. The principles themselves have not changed; only the tools and contexts in which we apply them have changed.
For a complete breakdown of what changed between ICH GCP E6 R2 and R3, see our guide to the key changes between ICH GCP E6 R2 and R3.
Key takeaways
The Belmont Report is the 1979 document that established the ethical foundation of all modern clinical research. Its three principles, respect for persons, beneficence, and justice, remain as relevant today as when they were written, and they underpin every requirement in the ICH GCP good clinical practice guidance that governs clinical trials worldwide.
Respect for persons requires that research participants are treated as autonomous agents capable of making their own decisions, and that those with diminished autonomy receive additional protections. This principle is the ethical basis of the entire informed consent framework in good clinical practice training.
Beneficence requires that researchers maximize benefits and minimize harms, not simply avoid harm, but actively design research to protect participants and maximize the knowledge generated. This principle underpins independent ethics committee review, adverse event monitoring, and the risk-benefit assessment at the heart of every protocol.
Justice requires the fair distribution of research burdens and benefits. Vulnerable or disadvantaged groups may not be targeted for research participation out of convenience, and groups who will benefit from the results must share equitably in the risks. This principle underpins requirements for diverse participant populations and is increasingly central to contemporary ICH GCP good clinical practice guidance.
The lineage from the Belmont Report to today’s good clinical practice guidance runs through the Declaration of Helsinki and ICH GCP E6, a direct ethical inheritance that means every GCP-certified clinical research professional is, in a meaningful sense, the inheritor of the lessons of Tuskegee, Nuremberg, and every other research ethics failure that preceded the Belmont Report.
Understanding this lineage does not simply make a clinical research professional more knowledgeable. It makes them more ethical, more likely to recognize when a protocol, a consent process, or a recruitment strategy falls short of the principles that make clinical research genuinely trustworthy.
Conclusion
The Belmont Report is not a historical curiosity. It is a living document whose three principles run through every ICH GCP good clinical practice training course, every ethics committee submission, every informed consent form, and every safety monitoring process in clinical research today. When a coordinator ensures a participant has genuinely understood the consent form. When an investigator flags a protocol requirement that may unfairly burden a vulnerable population. When an ethics committee refuses to approve a study that exposes participants to disproportionate risk. In each of these moments, the Belmont Report is present, not as a reference to be cited, but as the ethical reasoning that makes the action right.
For clinical research professionals, understanding the Belmont Report is part of understanding what they are actually doing when they follow ICH GCP requirements. The paperwork and the procedures exist for a reason, and the reason is to ensure that what happened in Tuskegee, what happened in Nazi concentration camps, what happened every time research was conducted on human beings without their knowledge, their consent, or their protection, can never happen again. That is the purpose of the Belmont Report. That is why good clinical practice exists. And that is why ICH GCP good clinical practice certification is not simply a professional credential, but an ethical commitment.
Understand ICH GCP at the level that the Belmont Report demands
Technical compliance is the floor of good clinical practice, not the ceiling. The best clinical research professionals do not simply follow ICH GCP requirements; they understand why those requirements exist, and they apply that understanding in every decision they make in the conduct of a clinical trial.
Our ICH GCP E6 R3 good clinical practice certification programme is designed to build exactly this depth of understanding. It covers not only the procedural requirements of the current ICH GCP E6 R3 guidance but also the ethical reasoning, rooted in the Belmont Report, the Declaration of Helsinki, and the history of research ethics, which makes those requirements meaningful.
Accredited by the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK) and approved by TransCelerate, our ICH GCP good clinical practice certification is recognized by sponsors and regulators worldwide.
Start with our 2026 ICH GCP certification guide if you want to understand the full certification pathway, or go straight to our courses to begin your ICH GCP good clinical practice training today.
Click here to get your ICH GCP E6 R3 certification today.
Have you already completed good clinical practice training under R2? Our R3 programme covers the updated ICH GCP principles, the strengthened ethics provisions, and everything you need to bring your knowledge and your certificate fully current with the 2025 standard.
FAQ: the Belmont Report
What is the Belmont Report?
The Belmont Report is a foundational document in research ethics published in 1979 by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research in the United States. It establishes three principles, respect for persons, beneficence, and justice, that must govern all research involving human participants. These principles underpin the ICH GCP good clinical practice guidance that governs clinical trials worldwide today.
What are the 3 principles of the Belmont Report?
The three principles of the Belmont Report are: respect for persons, which requires treating research participants as autonomous agents and providing additional protections for those with diminished autonomy; beneficence, which requires maximising benefits and minimising harms; and justice, which requires distributing the burdens and benefits of research fairly across populations. Together, these three principles form the ethical foundation of all modern clinical research.
What was the purpose of the 1979 Belmont Report?
The Belmont Report was written in direct response to the Tuskegee Syphilis Study, a forty-year study in which Black men with syphilis were deliberately denied effective treatment so that researchers could observe the disease’s progression. The purpose of the Belmont Report was to identify the ethical principles that had been violated in Tuskegee and other research abuses, and to ensure those principles were embedded in all future research involving human participants.
How does the Belmont Report relate to ICH GCP?
The Belmont Report is the ethical foundation on which the ICH GCP good clinical practice guidance is built. The three Belmont Report principles, respect for persons, beneficence, and justice, generate the specific GCP requirements for informed consent, independent ethics committee review, risk-benefit assessment, adverse event monitoring, and equitable participant selection. Every requirement in ICH GCP good clinical practice training can be traced back to one or more of the Belmont Report’s three principles.
What is the difference between the Belmont Report and the Declaration of Helsinki?
Both documents are foundational to research ethics, but they serve different functions and have different scopes. The Declaration of Helsinki, first published in 1964, is addressed to the medical profession and provides detailed practical standards for medical research. The Belmont Report, published in 1979, provides a philosophical framework, three principles from which all specific research ethics requirements can be derived, applicable across all types of research involving human participants. The two documents are complementary and together inform the ICH GCP ethical framework.
What is the Nuremberg Code and how does it relate to the Belmont Report?
The Nuremberg Code, published in 1947 following the Doctors’ Trials after World War II, was the first international statement that voluntary informed consent is an absolute requirement for human research. It was a direct response to Nazi medical experimentation in concentration camps. The Belmont Report built on the Nuremberg Code’s legacy by providing a systematic philosophical framework that extended beyond consent to encompass beneficence and justice, the two principles that address not only whether participants choose to participate but also whether the research treats them fairly and protects them from unnecessary harm.
Are the Belmont Report principles still relevant in modern clinical research?
Yes, the Belmont Report’s three principles are more relevant than ever. ICH GCP E6 R3, the current good clinical practice standard adopted in January 2025, strengthens several provisions that are direct expressions of Belmont Report principles: enhanced diversity requirements reflect the justice principle, quality by design reflects the beneficence principle, and the strengthened informed consent framework reflects the respect for persons principle. The Belmont Report’s principles are not historical artefacts but the living ethical foundation of contemporary clinical research practice.
How does the Belmont Report define informed consent?
The Belmont Report defines informed consent as comprising three elements: information, comprehension, and voluntariness. Information means that participants receive a complete and honest account of what the research involves. Comprehension means that the information is presented in a form that the participant can genuinely understand. Voluntariness means that the decision to participate is free from coercion, undue influence, or deception. All three elements must be present for consent to be genuinely informed in the ethical sense that the Belmont Report requires.
Do I need to know the Belmont Report for ICH GCP certification?
Understanding the Belmont Report is highly valuable for anyone completing ICH GCP good clinical practice training or pursuing ICH GCP good clinical practice certification. While ICH GCP certification examinations test knowledge of the technical requirements of the ICH GCP guidance, understanding the Belmont Report’s principles enables a deeper understanding of why those requirements exist, which is what distinguishes a genuinely ethical clinical research professional from one who simply follows rules. Many ICH GCP good clinical practice training programmes, including those designed for investigators and site personnel, explicitly address the Belmont Report as part of the ethical foundations of GCP.
What happened after the Belmont Report was published?
After the Belmont Report was published in 1979, its principles were rapidly incorporated into United States federal regulations governing research involving human subjects, most notably 45 CFR Part 46, known as the Common Rule, and the FDA’s equivalent regulations governing clinical research. Internationally, the Belmont Report’s influence was felt through its impact on the development of the ICH GCP good clinical practice guidance in the 1990s, which explicitly ground GCP requirements in the ethical principles of both the Belmont Report and the Declaration of Helsinki.
